CD180 Overexpression in Follicular Lymphoma

November 29, 2016 updated by: Hospices Civils de Lyon

CD180 Overexpression in Follicular Lymphoma Is Restricted to the Lymph Node Compartment

Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD). CD180 is an orphan member of the TLR family that modulates the signaling of several TLRs, but only limited studies have evaluated its expression by flow cytometry (FCM) in LPD.

Methods: Using a multiparameter FCM approach, biologists have assessed CD180 mean fluorescence intensity (MFI) in lymph nodes (LNs) and peripheral blood (PB) samples obtained from patients with follicular lymphoma (FL; LN/PB, n=44/n=15), chronic lymphocytic leukemia (CLL, n=26/n=21), mantle cell lymphoma (MCL, n=13/n=17), and marginal zone lymphoma (MZL, n=16/n=12). Specimens from non-tumoral PB and LN (n=8/n=12) were used as controls.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

184

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

99 LN (lymph nodes) and 65 PB (peripheral blood) samples obtained from patients diagnosed with LPDs in our institution between 2012 and 2014 were evaluated for CD180 expression by FCM. The diagnosis were made according to the WHO 2008 classification, including clinical and morphological analysis, immunophenotyping, and conventional and molecular cytogenetics (and/or fluorescent in situ hybridization). The diagnoses were follicular lymphoma (FL) (LN, n=44; PB, n=15), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL)/CLL (LN, n=26; PB, n=21), MCL (LN, n=13; PB,n=17), and MZL (LN, n=16; PB, n=12). All PB samples presented circulating neoplastic B-cells, and in several cases, the diagnosis was made at the same time in LN and PB FL, n=4; SLL/CLL, n=18; MCL, n=5. MZL, n=6.

Description

Inclusion Criteria:

  • Samples from patients with:

    • LF: Follicular lymphoma
    • MCL: Mantle cell lymphoma
    • CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia
    • MZL : splenic marginal zone
    • Clt :control B-cells

Exclusion Criteria:

  • Patient <18 years old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
LN Lymph nodes

Samples obtained from patients with :

LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells
PB peripheral blood

Samples obtained from patients with :

LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immunophenotype Analysis by Flow Cytometry of lymph nodes samples at inclusion
Time Frame: At inclusion, day 0.
Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).
At inclusion, day 0.
Immunophenotype Analysis by Flow Cytometry of peripheral blood samples at inclusion
Time Frame: At inclusion, day 0.
Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).
At inclusion, day 0.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

June 1, 2015

Study Registration Dates

First Submitted

August 29, 2016

First Submitted That Met QC Criteria

November 29, 2016

First Posted (Estimate)

December 1, 2016

Study Record Updates

Last Update Posted (Estimate)

December 1, 2016

Last Update Submitted That Met QC Criteria

November 29, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 69HCL16_0564

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Follicular Lymphoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe